Results 11 to 20 of about 464,460 (389)

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Journal of Thrombosis and Haemostasis, 2020
A relatively high mortality of severe coronavirus disease 2019 (COVID‐19) is worrying, and the application of heparin in COVID‐19 has been recommended by some expert consensus because of the risk of disseminated intravascular coagulation and venous ...
N. Tang, Huan Bai, Xing Chen, Jiale Gong, Dengju Li, Ziyong Sun   +5 more
semanticscholar   +1 more source

Different Anticoagulant Regimens, Mortality, and Bleeding in Hospitalized Patients with COVID-19: A Systematic Review and an Updated Meta-Analysis

Seminars in Thrombosis and Hemostasis, 2021
We conducted a systematic review and a meta-analysis to assess the association of anticoagulants and their dosage with in-hospital all-cause mortality in COVID-19 patients.
R. Parisi, S. Costanzo, A. Di Castelnuovo, G. de Gaetano, M. Donati, L. Iacoviello   +5 more
semanticscholar   +1 more source

Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19

New England Journal of Medicine, 2020
Prolonged aPTT in Patients with Covid-19 In this study, 20% of patients with Covid-19 had a prolonged activated partial-thromboplastin time.
L. Bowles, S. Platton, Nada Yartey, Minal Dave, Kurtis Lee, D. Hart, Vickie MacDonald, Laura Green, S. Sivapalaratnam, K. Pasi, P. Maccallum   +10 more
semanticscholar   +1 more source

Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum

Journal of Thrombosis and Thrombolysis, 2020
Coronavirus disease 2019 (COVID-19) is a viral infection that can, in severe cases, result in cytokine storm, systemic inflammatory response and coagulopathy that is prognostic of poor outcomes. While some, but not all, laboratory findings appear similar
G. Barnes, Allison E. Burnett, Arthur L. Allen, Marilyn Blumenstein, N. Clark, A. Cuker, William E Dager, S. Deitelzweig, S. Ellsworth, D. Garcia, S. Kaatz, Tracy Minichiello   +11 more
semanticscholar   +1 more source

Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2020
Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long‐standing standard of care in anticoagulation, vitamin K antagonist. DOACs are indicated for prevention and treatment of several cardiovascular conditions.
Ashley Chen, E. Stecker, Bruce A Warden
semanticscholar   +1 more source

Lupus anticoagulant is frequent in patients with Covid‐19

Journal of Thrombosis and Haemostasis, 2020
Patients hospitalized for Covid-19 severe infection are more prone to excessive coagulation activation leading to thrombotic events. Tang et al.1 discussed the importance of high D-dimer and Fibrin degradation product level to determine the patient ...
I. Harzallah, A. Debliquis, B. Drénou
semanticscholar   +1 more source

Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis

Journal of Thrombosis and Haemostasis, 2020
This guidance focuses on methodological aspects of lupus anticoagulant (LA) testing, as well as interpretation of results for clinicians. The main changes in how to test for LA compared with the International Society on Thrombosis and Haemostasis ...
K. Devreese, P. D. de Groot, B. de Laat, D. Erkan, E. Favaloro, I. Mackie, M. Martinuzzo, T. Ortel, V. Pengo, J. Rand, A. Tripodi, D. Wahl, H. Cohen   +12 more
semanticscholar   +1 more source

Ischemic Stroke despite Oral Anticoagulant Therapy in Patients with Atrial Fibrillation

Annals of Neurology, 2020
It is not known whether patients with atrial fibrillation (AF) with ischemic stroke despite oral anticoagulant therapy are at increased risk for further recurrent strokes or how ongoing secondary prevention should be managed.
D. Seiffge, G. M. De Marchis, M. Koga, M. Paciaroni, D. Wilson, M. Cappellari, Kosmas Macha, G. Tsivgoulis, G. Ambler, S. Arihiro, L. Bonati, B. Bonetti, B. Kallmünzer, K. Muir, P. Bovi, H. Gensicke, M. Inoue, S. Schwab, S. Yaghi, Martin M. Brown, P. Lyrer, Masahito Takagi, Monica Acciarrese, H. Jager, A. Polymeris, K. Toyoda, M. Venti, C. Traenka, H. Yamagami, A. Alberti, S. Yoshimura, V. Caso, S. Engelter, D. Werring   +33 more
semanticscholar   +1 more source

Consensus‐based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID‐19–related illness

Journal of Thrombosis and Haemostasis, 2020
Observational studies indicate that children hospitalized with COVID‐19‐related illness, like adults, are at increased risk for venous thromboembolism (VTE).
N. Goldenberg, A. Sochet, M. Albisetti, T. Biss, M. Bonduel, J. Jaffray, G. MacLaren, P. Monagle, S. O’Brien, L. Raffini, S. Revel-Vilk, N. Sirachainan, Suzan Williams, A. Zia, C. Male   +14 more
semanticscholar   +1 more source

Evidence supporting idarucizumab for the reversal of dabigatran. [PDF]

, 2016
Idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran. It has demonstrated prompt and durable reversal of the anticoagulant effects of dabigatran in animal studies and phase 1 studies of young, elderly, and renally impaired ...
Pollack, Charles V.
core   +2 more sources